Making breakthroughs happen
The work we support at The Royal Marsden is revolutionising the way cancer is diagnosed and treated for people everywhere.
1 in 2 of us will be diagnosed with cancer in our lifetime
This means we need to diagnose cancer earlier and develop better treatments more than ever before.
In the last 5 years, the Charity has awarded £30.4 million to The Royal Marsden for life-saving research into new, more effective cancer treatments.
Thanks to your donations, we're helping experts to develop the next generation of cancer treatment for people around the world.
Building on The Royal Marsden's legacy of innovation
Since 1851, The Royal Marsden has been paving the way in developing new treatments for cancer.
Today, we continue to build on a track record of life-saving research breakthroughs.
Tamoxifen
Tamoxifen, a hormone therapy drug for breast cancer, was trialled at The Royal Marsden in the 1980s. Since then, it's helped millions of patients around the world.
Chemotherapy
Chemotherapy drugs, such as carboplatin and busulfan, were developed at The Royal Marsden, with its principal academic partner, The Institute of Cancer Research, London (ICR).
These drugs are still widely used to treat cancer today.
Building on The Royal Marsden's legacy of innovation
Since 1851, The Royal Marsden has been paving the way in developing new treatments for cancer. Today, we continue to build on a track record of life-saving research breakthroughs.
Advances made here in all areas of cancer treatments including drug development, surgical techniques, and radiotherapy impact millions of people around the world.
Tamoxifen
Tamoxifen, a hormone therapy drug for breast cancer, was trialled at The Royal Marsden in the 1980s. Since then, it has helped millions of patients around the world.
Chemotherapy
Chemotherapy drugs, such as X and Y, that are still used widely today were developed at The Royal Marsden and our partner, The Institute of Cancer Research, London (ICR).
Developing the next generation of cancer treatments
We support experts at The Royal Marsden to make breakthroughs happen.
Thanks to your donations, we fund groundbreaking research into better treatment across a broad range of cancer types including diseases that are harder to treat, such as melanoma and sarcoma.
Between 2000-2016, The Royal Marsden and the ICR have been directly involved in 23% of licensed cancer drugs by the European Medicines Agency (EMA).
The Royal Marsden leads more than 900 clinical trials at any given time, improving patient treatment and care worldwide.
Earlier diagnosis for more successful treatment
Survival rates are increasing and people with cancer are receiving more tailored treatment, helping people to live well with cancer for longer.
But cancer is complex. And as the disease evolves, it can become harder to treat.
An earlier diagnosis offers patients more time. People with cancer can also receive treatment sooner, often with less side effects and less time in hospital.
Your donations fund research into earlier diagnosis and treatment that are less invasive for more precise, improved patient care.
Blood tests to detect risk of relapse
Your donations supported the TRAK-ER trial. This first-of-its-kind research trial explored how blood tests can be used for breast cancer patients to detect who may be at risk of relapse before the results appear on a scan.
Training AI to identify cancer
We supported the RADSARC-R research study. Results found that AI could be around twice as accurate as a biopsy to grade the aggressiveness of some sarcomas.
Make a Difference Today
Every donation takes us a step closer to another life-saving breakthrough.
Discover breakthroughs made possible by your generous support.
Drug derived from olive oil shows early promise in treating people with aggressive brain cancer
Results from an early-phase study led by The Royal Marsden and the ICR suggest the drug – 2-OHOA could offer new hope for glioblastoma patients.
Breakthrough research to cut treatment time for prostate cancer patients by incredible 75%
We supported the ‘practice-changing’ PACE-B clinical trial which showed that men with localised prostate cancer can be treated with 96% effectiveness in under two weeks.
First-ever cellular therapy for solid tumours approved for treatment of advanced melanoma
Thanks to an international research collaboration with The Royal Marsden, Lifileucel was the first-ever cellular therapy to be approved for the treatment solid tumours by the U.S. Food and Drug Administration (FDA) in 2024.
Your support is life-saving
Your generosity funds world-leading research to develop the next generation of cancer treatment for patients, everywhere.